← Back to Home

Teva settles US states' drug price-fixing case

Reuters
Teva settles US states' drug price-fixing case

Nov 16 (Reuters) - Teva Pharmaceutical Industries ‌has settled long-running litigation by most US states accusing the drugmaker and dozens ​of other ‌defendants of conspiring to fix prices on dozens ‌of generic drugs.

• Chief Judge Michael Shea of the federal court in Hartford, Connecticut, put the case ‌on hold on Monday after both sides reached an agreement in principle to settle, court records show. Settlement terms were not disclosed. The case was brought by ⁠45 US states, Washington, DC and two US ‌territories.

• Teva did not ⁠immediately respond to requests for comment. The office of Connecticut ​Attorney General William Tong, whose state leads the litigation, did not immediately respond to similar ​requests.

• The states accused Teva and other defendants ​of ‌having in 2012 "embarked on one of the most egregious ​and damaging price-fixing conspiracies in the history of ⁠the United States," in which they ‌allegedly agreed ​to maintain their "fair share" of ​each generic drug market while significantly raising prices on as many drugs as possible.

• Prices skyrocketed in 2013 and 2014, the states said. Teva significantly ‌raised prices on approximately 112 different generic drugs, and colluded with "high quality" competitors to raise prices on ‌at least ​86 of them, sometimes by more than 1,000%, the states added.

• Shea oversees two other antitrust lawsuits by state attorneys general related to generic drugs.

(Reporting by Jonathan ‌Stempel in New York; Editing by Chizu Nomiyama )